Vaccines (Jan 2021)

SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region

  • Angelo Musicò,
  • Roberto Frigerio,
  • Alessandro Mussida,
  • Luisa Barzon,
  • Alessandro Sinigaglia,
  • Silvia Riccetti,
  • Federico Gobbi,
  • Chiara Piubelli,
  • Greta Bergamaschi,
  • Marcella Chiari,
  • Alessandro Gori,
  • Marina Cretich

DOI
https://doi.org/10.3390/vaccines9010035
Journal volume & issue
Vol. 9, no. 1
p. 35

Abstract

Read online

A workflow for rapid SARS-CoV-2 epitope discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 positive sera were tested in the refinement processes, leading to the identification of immunodominant regions on SARS-CoV-2 spike (S), nucleocapsid (N) protein and Orf1ab polyprotein. A summary study testing 50 serum samples highlighted an epitope of the N protein (region 155–71) providing good diagnostic performance in discriminating Covid-19 positive vs. healthy individuals. Using this epitope, 92% sensitivity and 100% specificity were reached for IgG detection in Covid-19 samples, and no cross-reactivity with common cold coronaviruses was detected. Likewise, IgM immunoreactivity in samples collected within the first month after symptoms onset showed discrimination ability. Overall, epitope 155–171 from N protein represents a promising candidate for further development and rapid implementation in serological tests.

Keywords